Cellular big bang of multiple sclerosis

Florian Ingelfinger, an immunologist at the University of Zürich, has won the Pfizer Research Award. Ingelfinger was studying Multiple Sclerosis (MS), an autoimmunity disease causing inflammatory reactions in the central nervous system and the spinal […]


Recent publications by ZNZ members

Read here about recent papers published by members of the Neuroscience Center Zurich. Disentangling influences of dyslexia, development, and reading experience on effective brain connectivity in childrenNeuroimage. 2023 Mar;268:119869.  doi: 10.1016/j.neuroimage.2023.119869. Epub 2023 Jan 10.Authors: […]


Welcome to the community

We are proud to welcome our new members. Read on to learn about the research expertise they contribute to our community. Prof. Angelika Steger, Group Leader Institute of Theoretical Computer Science, ETH Zurich Neurons exhibit […]


Inaugural Lectures

We congratulate Christelle Le Foll, Katrin Frauenknecht, and Margarita G. Todorova on their inaugural lectures. In November, Christelle Le Foll talked about “Impact of fat on the brain: good or bad?“. In December, Katrin Frauenknecht […]


Konrad Akert Lecture 2023

The 3rd Konrad Akert lecture will be held by Li-Huei Tsai from the Massachusetts Institute of Technology. Li-Huei is an outstanding scientist who made a number of seminal discoveries in the context of memory formation […]

Research News

From nose to brain

Antibodies against specific target molecules or structures in the brain and spinal cord are currently reaching the stage of clinical application for several neurological diseases like Alzheimer’s, Parkinson’s, Multiple Sclerosis, and spinal cord injury. How […]


ETH medals for doctoral theses

Two doctoral theses at the ZNZ PhD Program in Neuroscience were awarded the ETH medal 2022. We congratulate the award winners and wish them all the best for their future research careers. The medal winners […]

Research News

Why clinical studies of Alzheimer’s fail

Amyloid-β pathology is believed to be a key component underlying Alzheimer’s Disease. However, most treatments that target amyloid-β have failed clinical trials. To systematically evaluate these treatments and possible reasons for failure, Adriano Aguzzi (USZ), […]